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Ten healthy volunteers (six males; four females) completed this double-blind, crossover design study of vigabatrin 
vs placebo. Subjects were tested on four oscasions; at the baselines of the placebo and the vigabatrin phase, and 
two weeks thereafter. At time of testing, the dose of vigabatrin was 2 g daily. Changes in cognition were assessed 
using the Sternberg, the PASAT, the Stroop, and Critical Fusion Flicker tests. Mood was assessed with the Mood 
Adjective Check List, the Beck Depression Inventory, and the Irritability, Depression and Anxiety scales. We 
found one drug, and one placebo, related significant difference on a measure of cognition. 
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INTRODUCTION 
Vigabatrin is one of the new antiepileptic drugs 
(AEDs) with a novel mode of action. It is known 
to inhibit GABA transaminase and reliably to 
increase GABA levels in the central nervous 
system’. 
It is known that anticonvulsant drugs can affect 
cognitive function*. In general, all of the standard 
AEDs have been shown to affect some aspect of 
cognition in patients with epilepsy, although there 
is some debate about the relative contribution of 
the different compounds3. 
Of the new agents, vigabatrin has been the 
most studied. Our group has carried out two 
previous studies of the effects of vigabatrin on 
various cognitive tests when given as add-on 
therapy to patients. McGuire et al4 used a 
computerised battery of attention and concentra- 
tion tasks, while Dijkstra et al5 selected essentially 
non-motor tasks. Neither study showed any 
detrimental effect of vigabatrin, and in each 
study, patient performance actually improved on 
one of the selected tasks. Other groups have also 
investigated the cognitive effects of vigabatrin in 
patients. Dodrill et af6 on a completely different 
test regime based largely on the Halstead-Reitan 
battery, noted no effects. Grunewald et af’ found 
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a small but significant impairment on only one of 
their cognitive tasks. 
A major problem of interpreting these studies 
relates to the effects of the drug on epilepsy 
variables. Vigabatrin is a powerful anticonvulsant 
rendering up to 10% of patients seizure free’. 
Such changes can influence cognition. Studies of 
volunteers are therefore helpful in interpreting 
the data which is collected in clinical investiga- 
tions. We have previously carried out volunteer 
studies on a number of AEDs9-“. It is possible, in 
a controlled environment, to carry out double- 
blind placebo investigations and interpret the 
results without having to consider extraneous 
illness variables. We present here the results of a 
volunteer study with vigabatrin. 
MATERIALS AND METHODS 
Eleven healthy volunteers were recruited to a 
double-blind crossover trial of vigabatrin vs. 
placebo. All met the exclusion criteria, having no 
current or past neurological or psychiatric prob- 
lems. One dropped out during the vigabatrin 
phase because of the development of a skin 
problem, considered unrelated to vigabatrin. 
The ten subjects who completed the study 
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included six males and four females with a mean 
age of 31.5 years. They were randomly allocated 
to two treatment groups. Group 1 (GVG/Plac) 
received active drug for two weeks. After a 
minimum one week washout phase, they were 
then given placebo matched tablets for a further 
two weeks. Group 2 (Plac/GVG) were treated in 
reverse order to Group 1. Vigabatrin was 
prescribed at 1 g, increasing after one week, to 2 g 
daily. 
Subjects were tested on four occasions; at the 
beginning and end of each of the two treatment 
phases. Cognition and mood were measured with 
tests detailed below. 
The Paced Auditory Serial Addition Task 
(PASAT) 
An audio-taped presentation of numbers is given 
at a set pace. Subjects have to add each digit to 
the one preceding it and answer aloud before the 
next number is presented. There are three 
different paces (2.0,1.6 and 1.2 seconds) and each 
presentation contains 50 number items. Scores 
are obtained by calculating the correct number of 
additions made for each presentation. It is a 
measure of information processing12. 
scores are obtained for correct and corrected 
answers. This test examines the competing 
demands for attention that one set of stimuli has 
on another, and requires concentration with an 
ability to suppress unwanted information14. 
The Sternberg 
A computer-generated series of digits is pre- 
sented sequentially and momentarily on screen. It 
is followed by a target number. Subjects have to 
identify whether the target number was present in 
the preceding series. Each series varies between 
two and six numbers. There are 60 presentations, 
Latency is measured in time taken to complete 
the task (l/6 seconds) and total scores are 
obtained by calculating the number of correct 
identifications. This is a memory scanning and 
attention task15. 
The mood adjective check list” 
This 24-item questionnaire yields a total mood 
score and five subscores measuring depression, 
anxiety, hostility, vigour and fatigue. 
The Beck depression inventory” 
Critical Fusion Flicker (CFF) 
Using the ‘up’ mode of the portable Leeds 
Psychomotor tester, four LEDs flicker at an 
increasing speed (cycles per second). Subjects 
have to respond when the lights appear to be 
stationary. In the ‘down’ mode, the apparently 
stationary lights flicker at a decreasing speed and 
subjects have to respond when the lights first 
appear to flicker. Six presentations are made in 
each mode, which are repeated once, to give two 
modal score totals. These are added together to 
give a total score. It is a task of central integrating 
ability, known to be sensitive to sedative and 
stimulant effects13. 
The Stroop colour-word task 
This is a two task test. Firstly, subjects are asked 
to read a list of colour words (printed in 
incongruent ink) in two minutes. In the second 
task, they are asked to name the ink colour, which 
is incongruent with the actual colour word. 
Latency is measured as time taken to complete 
each task, (with a cut off at 120 seconds), whilst 
This l&item questionnaire yields a total score for 
depression. 
Statistical analysis of a crossover trial design 
requires that before treatment effects can be 
compared, period effects and treatment-period 
interaction effects are investigated”. This was 
done by f-tests, comparing the differences be- 
tween periods in the two groups (a period effect), 
and the average scores of the two treatments in 
the order that they were given (a treatment- 
period interaction effect). Paired r-tests were then 
applied to make treatment comparisons. 
RESULTS 
t-tests revealed significant treatment differences 
between baseline and vigabatrin scores on the 1.6 
seconds PASAT (P = 0.004), as well as between 
baseline and placebo scores on the 1.2 seconds 
PASAT (P = 0.008). 
There was a significant period effect on the 
Stroop colour-word score (P = 0.03), the 2.0 
seconds PASAT (P = O.OS), and the Sternberg 
latency (P = 0.01). In addition, treatment-period 
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Table 1: Baseline & Treatment Scores of Coanitive & Mood Tests 
Sternberg 
BaseGVG GVG 2g Base/Plac Placebo 
Mean SD Mean SD Mean SD Mean SD 
Latency (l/6 sets) 
Score 
CFF 
UP 
Down 
Total 
STROOP 
Latency (sets) 
Score 
PASAT 
2.0 sets 
1.6 sets 
1.2 sets 
BECK 
Total 
IDA 
W 
Anx 
0 Host 
I Host 
Total 
MACL 
D-v 
Anx 
Host 
Vig 
Fat 
Total 
4361.5 1060.7 4272.2 
63.9 3.0 62.6 
26.1 1.5 26.2 
26.3 1.9 25.1 
26.2 1.2 25.7 
104.8 16.9 101.6 
105.5 9.7 109.2 
40.6 8.4 43.1 
37.1 7.4 41.0** 
33.3 7.4 35.0 
5.3 
3.8 3.7 4.1 
3.8 3.5 4.1 
3.2 1.7 4.1 
2.1 3.0 2.3 
12.9 9.3 14.6 
2.4 4.6 3.6 
1.8 2.0 2.2 
1.0 1.6 1.5 
5.5 3.3 5.1 
3.6 2.8 3.8 
14.3 6.1 16.2 
9.3 5.9 
928.2 4052.4 529.8 4035.1 
9.0 65.5 2.0 63.6 
2.5 27.1 2.4 27.3 
2.1 25.9 2.8 25.6 
2.1 26.5 2.2 26.4 
16.3 101.4 13.9 105.9 
4.5 107.3 8.3 110.5 
7.4 41.5 8.6 43.6 
8.4 39.6 8.8 40.1 
7.9 33.9 7.4 38.0* 
11.0 6.0 7.6 5.5 
3.9 3.7 2.2 3.6 - 
3.6 3.9 2.8 4.3 
2.7 3.5 2.1 3.2 
3.2 2.6 3.1 2.2 
11.8 13.7 7.5 13.3 
7.3 3.4 4.8 1.4 
2.4 2.2 2.5 2.0 
1.8 1.4 1.8 1.1 
4.1 5.4 2.9 4.7 
3.0 3.5 2.8 2.7 
11.3 15.9 7.6 13.0 
656.0 
5.9 
2.0 
2.2 
1.5 
18.8 
2.8 
8.4 
10.9 
8.8 
7.5 
2.4 
3.4 
2.2 
3.0 
9.8 
2.1 
1.4 
1.7 
3.0 
2.1 
5.3 
** P < 0.01; *P < 0.05. (Treatment differences) 
interaction effects were noted on the MACL 
vigour (P =0.03) and the IDA hostility (P = 
0.02) (see Table 1). 
DISCUSSION 
The data supports the clinical studies which 
suggest that vigabatrin has minimal or no adverse 
consequences for some aspects of cognition. In 
this study we noticed a significant improvement 
with vigabatrin, on the 1.6 second PASAT test. 
This was interesting because in our patient tria15, 
we had reported improvements on this test at 
1.2 seconds, whilst in this study, there was a 
significant placebo effect at this speed. The data 
suggests that these may be chance effects. 
The essentially negative results (see Table l), 
may have been related to a time factor; we were 
only giving vigabatrin for 14 days, and our patient 
studies were done at 28 days. It is possible that 
psychotropic effects emerge thereafter. However, 
the biochemical effects of vigabatrin clearly 
emerge within a few days of starting treatment’, 
and in a sub-group of patients in whom behaviou- 
ral problems emerged following treatment with 
vigabatrin, effects were reported in some patients, 
following a few doses (Thomas er al unpubl. res.). 
Alternatively, the beneficial effects on cognition 
in patients with epilepsy, may have been related 
to improved cerebral function, also reflected in 
diminishing seizure frequency in some patients in 
those studies. 
The test battery we selected for the volunteer 
studies was one that we had earlier used in one of 
the patient studies’ which was composed of tests 
with minimal motor effects and examined some 
components of higher cognitive function, particu- 
larly attention and concentration. These tests 
have been shown to be susceptible to the 
influence of anticonvulsant drugs’,” (Kendrick er 
al unpubl. res.). It is possible that with the use of 
other tests, some changes may have been 
detected, but the results as presented here are in 
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keeping with the accumulating data on vigabatrin 
and cognitive function, namely that of all of the 
anticonvulsant drugs that have been examined so 
far, it appears to have no obvious adverse effect8. 
It could be argued that the small sample size of 
our study provides low statistical power to detect 
change. We were constrained by ethical con- 
siderations to examine our data on ten patients, 
and our essentially negative findings did not lead 
us to believe that increasing our sample size 
would have revealed meaningful significant 
differences. Furthermore, the dose of 2g was 
considered a reasonable equivalent to clinical 
practice, and so we did not subject volunteers to 
higher doses. 
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